Linaglip M 2.5/500mg Tablet 1 Strip

✔️ Uses of Linaglip M 500

• Type 2 diabetes mellitus
• Helps improve blood sugar control when used with diet and exercise

✔️ Mode of Action

Linagliptin: Linagliptin inhibits the DPP-4 enzyme, which normally breaks down the incretin hormones GLP-1 and GIP. By prolonging incretin activity, it promotes glucose-dependent insulin release and reduces glucagon secretion, helping lower blood glucose.

Metformin: Metformin reduces glucose production by the liver, decreases intestinal glucose absorption, and improves insulin sensitivity in body tissues. It lowers both fasting and after-meal blood glucose and generally does not cause hypoglycemia when used alone.

✔️ Linagliptin and metformin may interact with certain medicines.

• Rifampicin may reduce linagliptin exposure and its blood-glucose-lowering effect.
• Ritonavir may increase linagliptin levels.
• Linagliptin can affect the transport or metabolism of certain medicines, including digoxin and some CYP3A4 substrates.
• Cimetidine and other medicines eliminated through renal tubular secretion may increase metformin exposure.
• Iodinated contrast agents administered into the bloodstream may increase the risk of kidney problems and metformin-associated lactic acidosis.
• Excessive alcohol intake may increase the risk of lactic acidosis associated with metformin

✔️ Side Effects:

• Diarrhea
• Nausea
• Vomiting
• Stomach discomfort or indigestion
• Headache
• Stuffy or blocked nose
• Sore throat
• Nasopharyngitis or respiratory tract infection
• Low blood sugar (hypoglycemia), particularly when used with insulin or sulfonylureas

✔️ How to Take Linaglip M 500

Take Linaglip M 500 exactly as prescribed by your doctor. Swallow the tablet whole with water. Do not crush, chew, or break the tablet. It should generally be taken with food to minimize gastrointestinal discomfort.

✔️ Dosage & Administration:

Adult Dose

The dosage should be individualized according to the patient's blood glucose control, current metformin dose, tolerability, kidney function, and other diabetes treatments.

For immediate-release linagliptin/metformin combinations, the usual starting dose may be 2.5 mg/500 mg twice daily in patients who are not already taking metformin. For patients already receiving metformin, the dose should be selected according to their current metformin regimen.

The total daily dose should not exceed the recommended maximum of 5 mg linagliptin and 2,000 mg metformin.

For extended-release formulations, dosing is individualized and should remain within the recommended maximum daily dose.

Children

The safety and effectiveness of linagliptin/metformin in individuals below 18 years of age have not been established.

Renal Impairment

Kidney function should be assessed before starting treatment with metformin.

• eGFR below 30 mL/min/1.73 m²: Contraindicated
• eGFR 30–45 mL/min/1.73 m²: Starting treatment is generally not recommended
• Kidney function should be monitored periodically, particularly in elderly patients or those at increased risk of kidney problems.
• If kidney function declines significantly during treatment, the doctor should reassess whether continuing the medicine is appropriate.

Hepatic Impairment

Use is generally not recommended in significant hepatic impairment because of the increased risk of metformin-associated lactic acidosis.

✔️ Linaglip M 500 should not be used in patients with:

• Allergy or hypersensitivity to linagliptin, metformin, or any component of the medicine
• Type 1 diabetes mellitus
• Diabetic ketoacidosis or diabetic pre-coma
• Severe renal impairment
• Significant hepatic impairment
• Acute alcohol intoxication or excessive alcohol use
• Acute conditions that may significantly affect kidney function, such as severe dehydration, serious infection, or shock
• Conditions associated with reduced tissue oxygenation, such as severe cardiac or respiratory failure or recent myocardial infarction

✔️ Use Linaglip M 500 with caution and under medical supervision in patients with:

• Kidney impairment
• A history or symptoms suggestive of pancreatitis
• Risk of hypoglycemia, particularly when combined with insulin or sulfonylureas
• Conditions that increase the risk of lactic acidosis
• Planned surgery or procedures requiring anesthesia
• Use of iodinated contrast media
• Pregnancy
• Older age
• Breastfeeding

✔️ Storage:

Store Irban 5 mg Tablet tablets at room temperature